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Background: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the
renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An
inhibitor of this pathway would enhance urinary glucose excretion (UGE), and potentially improve plasma glucose
concentrations in diabetic patients. RE is intended for use for the treatment of type 2 diabetes mellitus (T2DM) as
monotherapy and in combination with existing therapies. Metformin, a dimethylbiguanide, is an effective oral
antihyperglycemic agent widely used for the treatment of T2DM.
Methods: This was a randomized, open-label, repeat-dose, two-sequence, cross-over study in 13 subjects with
T2DM. Subjects were randomized to one of two treatment sequences in which they received either metformin
alone, RE alone, or both over three, 3-day treatment periods separated by two non-treatment intervals of variable
duration. On the evening before each treatment period, subjects were admitted and confined to the clinical site for
the duration of the 3-day treatment period. Pharmacokinetic, pharmacodynamic (urine glucose and fasting plasma
glucose), and safety (adverse events, vital signs, ECG, clinical laboratory parameters including lactic acid)
assessments were performed at check-in and throughout the treatment periods. Pharmacokinetic sampling
occurred on Day 3 of each treatment period.
Results: This study demonstrated the lack of effect of RE on steady state metformin pharmacokinetics. Metformin
did not affect the AUC of RE, remogliflozin, or its active metabolite, GSK279782, although Cmax values were slightly
lower for remogliflozin and its metabolite after co-administration with metformin compared with administration of
RE alone. Metformin did not alter the pharmacodynamic effects (UGE) of RE. Concomitant administration of
metformin and RE was well tolerated with minimal hypoglycemia, no serious adverse events, and no increase in
lactic acid.
Conclusions: Coadministration of metformin and RE was well tolerated in this study. The results support continued
development of RE as a treatment for T2DM.
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Type 2 diabetes mellitus (T2DM) is a chronic disease char-
acterized by deteriorating glycemic control and an associ-
ated risk of complications. Evidence from controlled
clinical trials suggests that improving glycemic control can
substantially reduce the long-term microvascular complica-
tions of diabetes [1-5]. Current guidelines recommend that
T2DM patients should be initially managed with diet and
exercise followed by pharmacological treatment with met-
formin as the preferred step 1 agent, unless there are con-
traindications to metformin use. When glycemic goals are
not achieved, the dose of metformin is increased or a sec-
ond agent is added [6,7]. In this treatment algorithm, suit-
ability for combination with metformin becomes a critical
concern in developing new antidiabetic agents.
Metformin is a dimethylbiguanide that reduces elevated
blood glucose levels primarily through its effects on redu-
cing hepatic glucose production and improving peripheral
tissue sensitivity to insulin. Metformin is typically adminis-
tered with meals and has an oral bioavailability of approxi-
mately 40 to 60% [8]. It undergoes extensive renal excretion
3 times the glomerular filtration rate [9] and has a mean
plasma elimination half-life between 4.0 and 8.7 hours.
There are no clinically relevant metabolic interactions
reported with metformin, and it is neither metabolized nor
inhibits the metabolism of other drugs [10]. However, there
are several transporter related drug interactions, in particu-
lar with cationic drugs that have been reported [9]; these
typically don’t require a dose adjustment. The main adverse
event of clinical concern with metformin is lactic acidosis, a
potentially life-threatening side effect that may be associ-
ated with high plasma concentrations of metformin and
renal insufficiency [11-13].
The low-affinity, high-capacity sodium-dependent glu-
cose co-transporter-2 (SGLT2), which is expressed specific-
ally in the renal proximal tubule [14,15], plays a major role
in the reabsorption of glucose by the kidney. SGLT2 has re-
cently gained recognition as a potential therapeutic target
for reducing hyperglycemia in T2DM, and several selective
SGLT2 inhibitors are being evaluated in the clinic [16-22].
In diabetic animal models, pharmacological inhibition of
SGLT2 leads to glucosuria followed by normalization of
plasma glucose levels and consequent improvement in in-
sulin resistance [23-25]. This mechanism may provide im-
provements in both fasting and postprandial hyperglycemia
without causing weight gain or other dose-limiting side ef-
fects observed with other oral antidiabetic approaches [26].
Remogliflozin etabonate is the prodrug of the highly se-
lective and potent SGLT2 inhibitor, remogliflozin. Adminis-
tration of remogliflozin etabonate has been shown to
increase urinary glucose excretion in a dose-dependent
manner in mice and rats and to exhibit antidiabetic efficacy
in several diabetic rodent models [27]. Remogliflozin is fur-
ther metabolized to GSK279782, which is an equally potentinhibitor of SGLT2 [28] but circulates at approximately
20% of the plasma concentrations of remogliflozin; thus
GSK279682 is expected to contribute to some of the ob-
served SGLT-2 inhibitor pharmacology. Single oral doses of
remogliflozin etabonate up to 1000 mg in healthy subjects
and repeated dosing in subjects with T2DM (up to 1000
mg BID for 2 weeks) have been safe and well tolerated
[29,30]. Remogliflozin etabonate is intended for use in the
treatment of T2DM as monotherapy. Given its mechanism
of action, it would be a candidate for combination withmet-
formin and other antidiabetic therapies as well. The os-
motic diuresis associated with increased urine glucose
excretion provides a potential mechanism for pharmacoki-
netic drug–drug interactions due to the extensive renal
clearance of metformin, although treatment with the diur-
etic hydrochlorothiazide for 2 weeks had no significant
effect on the clearance of metformin in subjects with
T2DM [31].
This study was designed to evaluate the effect of
remogliflozin etabonate on metformin exposure in T2DM
subjects. Secondarily, the effect of metformin on steady
state plasma concentrations of remogliflozin etabonate,
remogliflozin (active entity) and the active metabolite,
GSK279782 was evaluated. Three days of dosing (total of 5
doses) was considered adequate to achieve steady-state
conditions for both metformin and remogliflozin. Safety
problems that might be related to a pharmacokinetic drug–
drug interaction were also monitored.
Methods
This single-center, Phase 1 study was conducted at
Medica Sur Hospital and Clinical Foundation Pharma
Unit (CIF-BIOTEC), Mexico. This study was approved
by the investigational center ethics committee (Hospital
Medical Sur Ethics Committee) and was conducted in
accordance with Good Clinical Practice and the princi-
ples of the Declaration of Helsinki. All subjects provided
their written informed consent before study participa-
tion. The study was registered at http://clinicaltrials.gov
with the identifier NCT00376038.
Subjects
Male and female subjects (post-menopausal women or pre-
menopausal women with documented hysterectomy or
tubal ligation) with documented T2DM (≥3 months), ran-
ging in age from 30 to 64 years and with a body mass index
of 22 to 35 kg/m2, were eligible for the study. Enough sub-
jects were to be enrolled to ensure completion of at least
12 evaluable subjects. Pre-study screening included a med-
ical history, physical examination, medical and laboratory
evaluations, including 12-lead ECG, and a urinary drug
screen. Subjects were required to be free of clinically signifi-
cant medical and laboratory abnormalities, to have
glycosylated hemoglobin (HbA1c) <10%, and fasting plasma
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alone or metformin. Standard exclusion criteria concerning
blood donation, alcohol and drug use, caffeine intake, and
participation in other recent investigational drug studies
were applied. In addition, subjects were excluded from par-
ticipation in the study if they required insulin, had received
insulin within the past 3 months, or if they had significant
renal disease (as manifested by one or more of the follow-
ing: creatinine clearance <60 mL/min/1.73 m2, urine albu-
min concentration ≥300 μg/mg of creatinine, or a spot
urine sample with a urine protein/creatinine ratio >2.5 mg/
mg (a ratio that approximates the common cut off of 3 g of
protein in urine per 24 hours to exclude subjects with
nephrotic range proteinuria [32]).Study design
The study was a randomized, open-label, repeat-dose, two-
sequence, cross-over study in subjects with T2DM who
were taking metformin or who were drug naive. Before
randomization, eligible subjects were stratified on the basis
of their pre-entry treatment regimen: metformin or drug
naive. Subjects were randomized to receive one of two
treatment sequences depicted in Table 1. Each treatment
sequence included three treatment regimens [A =metfor-
min 500 mg every 12 hours (MET BID), B = remogliflozin
etabonate 500 mg every 12 hours (RE BID), and C =met-
formin 500 mg + remogliflozin etabonate 500 mg every 12
hours (MET +RE)] administered over three 3-day dosing
periods that were separated by two non-treatment intervals
of variable duration (minimum of 2 days up to a maximum
of 15 days). The last dose of drug for each study period was
before breakfast on day 3. Metformin was administered as
Glucophage® (Bristol-Myers Squibb, New York, NY) and
subjects were allowed to continue taking metformin during
the non-treatment interval between the first and second
treatment periods. On the evening before each treatment
period, subjects were admitted and confined to the clinical
site for the duration of the 3-day treatment period. Pharma-
cokinetic (PK), pharmacodynamic (PD; urine glucose and
FPG), and safety (adverse events, vital signs, ECG, clinical
laboratory parameters including lactic acid) assessments
were performed at check-in and throughout the treatment
periods. For each treatment period, the PK sampling
occurred on Day 3.Table 1 Treatment sequence regimens
Treatment
sequence
Period 1 Interval between dosing
3 Days 2 to 15 days
1 A Continue metformin only
2 C Continue metformin only
Treatment A (MET BID): Metformin IR 500 mg every 12 hours. Treatment B (RE BID):
Metformin IR 500 mg every 12 hours + remogliflozin etabonate 500 mg every 12 ho
1 and stopped after the morning dose on Day 3 of Period 2. For any Treatment Per
dosing was stopped after the morning dose was given on Day 3.Subjects were asked to refrain from drinking grapefruit
juice or eating grapefruit for at least 3 days before the first
dose until collection of the final PK sample for each treat-
ment period. Subjects were to abstain from alcohol or
caffeine- or xanthine-containing products from up to 24
hours prior to admission until collection of the final blood/
urine sample. Subjects who smoked had to be able to ab-
stain from use of tobacco products for the 12-hour PK
sampling interval. On days 1–3 of each treatment regimen,
while in-house, subjects were fed breakfast, lunch, and din-
ner as standard meals with identical meals provided on the
PK sampling days. Subjects were given 1700 kcal per day,
with calories distributed as 55% carbohydrate, 25% fat, and
20% protein. Breakfast was served at approximately 7am
and dinner at approximately 7 pm. Subjects were instructed
to complete these meals within 30 minutes. Within 15 mi-
nutes of completing the meal, the study medications were
administered with 240 mL of water per the randomization
schedule. Use of the following concomitant medications
was allowed if the dosing regimen had been stable for at
least 3 months prior to study enrollment: 3-hydroxy-3-me-
thyl-glutaryl-CoA reductase inhibitors, ACE inhibitors,
angiotensin receptor blockers, hydrochlorothiazide (dose of
≤25 mg/day), calcium channel blockers, alpha or beta
blockers, thyroid hormone (only if TSH in normal range),
hormone replacement therapy, inhaled and intranasal corti-
costeroids, antidepressants (SSRIs only) and multivitamins.
Low-dose acetaminophen or ibuprofen (≤1.2 g/day), and
any medications prescribed for treatment of adverse events
occurring during the study were also allowed. Concomitant
medications were not permitted within 4 hours of study
drug administration.
Clinical and laboratory monitoring for safety
For each treatment period, subjects were admitted to the
clinical facility on the evening of Day −1 to undergo check-
in procedures including a physical examination, 12-lead
ECG, vital signs, clinical laboratory tests (chemistry,
hematology and urinalysis), lactic acid measurement,
fasting blood glucose measurement, alcohol screen, drugs
of abuse screen and pregnancy test (if applicable). On each
study day morning, a fasting blood sugar measurement was
determined by glucose monitor. On Days 1 and 2, vital
signs and a 12-lead ECG were recorded. Samples for clin-
ical laboratory measure were also taken on Days 1 and 3.Period 2 Interval between dosing Period 3
3 days 2 to 15 days 3 days
C Stop all trial medications B
A Stop all trial medications B
Remogliflozin etabonate 500 mg every 12 hours. Treatment C (MET + RE BID):
urs. Metformin was administered starting from the morning of Day 1 of Period
iod when remogliflozin etabonate was administered, remogliflozin etabonate
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dosing day for a follow-up physical examination and labora-
tory evaluation. During the between-treatment intervals,
subjects were provided with glucose monitors to measure
fasting blood glucose concentrations; subjects were
instructed as to how to recognize and treat symptoms of
hypoglycemia. Adverse events were monitored throughout
the entire study (randomization to follow-up visit). Any ad-
verse events reported during the study were assessed by the
investigator for intensity (mild, moderate, severe) and rela-
tionship to the study drug (causality). Where possible, all
adverse events were followed until stabilization, resolution,
or until the event was otherwise explained.
Pharmacokinetic assessment
Blood sampling
Serial blood (two 2 mL samples for metformin and for
remogliflozin etabonate andmetabolites) were collected pre-
dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
for determination of plasma metformin, remogliflozin
etabonate (prodrug), remogliflozin (active entity) and
GSK279782 (metabolite) concentrations. All sample times
are relative to the time of the administration of the first dose
of study medication on Day 3 of each period. Blood samples
for metformin were collected into tubes containing EDTA
and immediately placed on ice and centrifuged at approxi-
mately 3000 rpm for 10 minutes at approximately 4°C. The
harvested plasma was separated, frozen and stored at −20°C
or lower until analysis for metformin concentrations. Blood
samples for remogliflozin etabonate, remogliflozin and
GSK279782 were collected into tubes containing potassium-
oxalate/ sodium fluoride, placed on ice and centrifuged at ap-
proximately 3000 rpm for 10 minutes at approximately 4°C.
The harvested plasma was frozen at −70°C until analysis for
remogliflozin etabonate, remogliflozin and GSK279782
concentrations.
Drug assays
The concentrations of remogliflozin etabonate, remogliflozin,
and GSK279782 in deproteinized plasma samples and
standards were determined by high-performance liquid chro-
matography (HPLC) with tandem mass spectrometry (MS/
MS) using isotopically labelled internal standards ([2H7]-
remogliflozin etabonate, [2H7]- remogliflozin and [
2H7]-
GSK279782 as previously described [28].
The concentrations of metformin in plasma were deter-
mined by HPLC-MS/MS using a [2H6]-metformin isotopic-
ally labelled internal standard. Plasma proteins from a 50
mL plasma aliquot were precipitated using acetonitrile
containing the internal standard (200 ng mL-1). Samples
were vortex mixed then centrifuged. The resulting super-
natant was transferred and mixed with 200 mL of HFBA
buffer (water containing 10 mM ammonium acetate and
0.26% (v/v) of heptofluorobutyric acid) prior to injection.HPLCwas performed on a Shimadzu LC-10AHPLC system.
Chromatography was performed on a MAC-MOD Ace 3
C18, 4.6 × 50 mm column at a flow rate of 1.0 mLmin-1. An
isocratic mobile phase elution with 82:18 (v/v) HFBA buffer :
Acetonitrile was used. Samples were analysed in positive ion
mode by Turbo Ionspray LC/MS/MS with a PE/Sciex API
3000. The calibration range was 20 to 5000 ng mL-1. Per-
formance of the method was assessed during a 3 day valid-
ation study using quality control samples at 5 concentrations
20, 80, 500, 4000 and 5000 ng mL-1. The average within-run
precision [coefficient of variation (CV %)] was <9.6% and the
between-run precision CV% was < 4.7%. Similar assay per-
formance was observed during study sample analyses.
Pharmacokinetic calculations
PK analyses of plasma concentration–time data of each
analyte (i.e., metformin, remogliflozin etabonate,
remogliflozin, and GSK279782) were conducted using
the noncompartmental Model 200 (for extravascular ad-
ministration) of WinNonlin Professional Edition version
4.1 (Pharsight Corporation, Mountain View, CA, USA).
Actual elapsed time from dosing was used to estimate all
individual plasma PK parameters. Values for the follow-
ing PK parameters were estimated for each analyte, as
appropriate, following administration of 3 days dosing of
metformin, remogliflozin etabonate, or both.
 Cmax and tmax were the actual observed values.
 AUC(0–12) or AUC(0–last) was calculated by a
combination of linear and logarithmic trapezoidal
methods. The linear trapezoidal methodwas used for all
incremental trapezoids arising from increasing
concentrations and the logarithmic trapezoidal method




FPG concentrations were collected on Day −1, 1, 2 and 3.
Changes in plasma glucose from baseline (Day 1) to Day 2
and 3 were calculated.
Urine PD
Urine was collected on Days 1 to 3 of each treatment
period, and urine glucose concentrations were analyzed for
the following intervals: 0–4 hours, 4–8 hours, 8–12 hours
and 12–24 hours. The quantity of glucose and creatinine
excreted in urine was determined by multiplying the urine
glucose or creatinine concentration for each time interval
by the volume of urine for the corresponding collection
interval. The total 24-hour quantity of glucose excreted in
urine on Day 2 was calculated by adding the amounts col-
lected during each interval. Urine glucose and creatinine
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for the total 24-hour collection period.
Creatinine clearance (CLcr) was calculated on Day 2
and used to determine the percent of filtered glucose
load excreted in urine. By using the urine collections on
Day 2, CLcr was calculated as follows:
Clcr ¼ total amount of urine creatinine 0 xxh interval
=nearest associated serum creatinine
¼ ðurine creatinine mg=xx hoursð Þ
=serum creatinine mg=dLð ÞÞ100 mL=dLÞ
= xx60ð Þ minutes=xx hoursð Þ;
where urine creatinine (mg/xx hours) is the amount of
urine excreted in a xx-hour period. Urine creatinine was
calculated by multiplying the urine creatinine concentra-
tion by the urine volume (mL) for a 0-xxh time interval
as follows:
urine creatinine mg=xx hoursð Þ
¼ urine creatinine concentration mg=dLð Þ
interval volume mLð Þ=100 mL=dLð Þ:ð
CLcr was reported in mL/minutes on Day 2 for col-
lection intervals 0–4 hours, 4–8 hours, 8-12 hours, 12–
24 hours, and the total daily interval of 0–24 hours.
The serum creatinine concentration used for the above
calculations was the pre-dose value for the same day
as the urine collection or the one closest to the day of
urine collection if no serum creatinine was collected on
that day.
Percent of filtered glucose excreted in the urine
Percent of filtered glucose excreted in the urine was esti-
mated for all collection intervals on Day 2 as follows:
Glucose Amount Excretedð Þ= ClcrPGTime Intervalð Þ or
Urine glucose mg=dLð ÞSerum Creatinine mg=dLð Þ½ =
urine creatinine mg=dLð ÞPG mg=dLð Þ½ 
where glucose amount excreted is the amount of glucose
excreted during the xx-hour period, and CLcr is calcu-
lated for the xx-hour time interval. PG is the plasma glu-
cose concentration reported closest to the midpoint of
the time interval. Because only pre-dose PG was col-
lected in this study, the pre-dose PG on Day 2 was used.
Time interval is the number of minutes of urine collec-
tion for that interval.
Total fluid intake, urine volume, and fluid balance (intake
minus output) were summarized over the 0–24-hour inter-
val of Day 1 and Day 2 and the 0–12-hour interval of Day 3
of each treatment period.Statistical analysis
The sample size was based on the primary endpoint, met-
formin AUCs(0–12) and assumed a within-subject standard
deviation of 0.15 [33,34] for natural log-transformed AUC .
Using the two one-sided t-test [35] at type I error α=0.05
under a crossover design, 12 subjects should provide at
least 90% power to demonstrate lack of an interaction if
the ratio of test to reference is truly 1 and the equivalence
criteria for the 90% confidence interval (CI) is 0.8–1.25.
Safety and PD parameters were summarized using
descriptive statistics. Analyses of steady-state plasma
metformin AUC(0–12) and Cmax were conducted with
metformin alone as the reference treatment. A mixed
effect model with ln(AUC(0–12)) as the dependent
variable; treatment, period and sequence as fixed ef-
fects; and subject-within-sequence as a random effect
was used to estimate the treatment difference and its
associated 90% CI on the log scale. The PROC MIXED
from SAS (Version 8.2, Cary, NC, USA) was used to fit the
model. The estimates and the 90% CI were exponentiated
in order to obtain the ratio of geometric means and its CI.
The assumptions underlying the model were assessed by
visual inspection of residual plots.
Similar analyses were performed for the secondary PK
endpoints for remogliflozin etabonate, remogliflozin and
its metabolite, with and without metformin. Tmax was
analysed non-parametrically using Hodges–Lehmann
method [36,37].
Results
Thirteen subjects (7 females [54%] and 6 males [46%])
were randomized and completed the study. Of these 13
subjects, 10 subjects were being treated with metformin
before study entry and three subjects were drug naive
before study entry. The median age was 54 years (range
38 to 62 years); the median BMI was 29 kg/m2 (range
22.5 to 34.3 kg/m2); mean fasting plasma glucose at base-
line was 7.21 mmol/L (SD 1.77; range 4.8 to 10.9 mmol/L).
All subjects were Hispanic or Latino.
Pharmacokinetics
The summary data of PK parameters for metformin,
remogliflozin etabonate, remogliflozin and GSK279782
are presented in Table 2. The primary PK objective was
to demonstrate a lack of effect of remogliflozin etabonate
on the PK parameters of metformin. Results from the
primary comparison, are summarized in Table 3 and
mean concentration vs time profiles are shown in Figure 1.
There was no effect of remogliflozin etabonate on metfor-
min PK parameters.
One of the secondary objectives included a comparison
of PK parameters for remogliflozin etabonate, remogliflozin
and GSK279782 after treatment with remogliflozin
etabonate alone and with MET+RE. A summary of these
Table 2 Summary of plasma metformin, remogliflozin etabonate, remogliflozin, and GSK279782 PK parameters
Metformin PK parameter MET BID MET + RE BID
N = 13 N = 13
AUC(0–12) (h.ng/mL) 7141.3 (24) 7520.8 (27)
Cmax (ng/mL) 1018.2 (26) 1025.3 (25)
tmax (h) 4.0 (1.0 - 6.0) 4.0 (1.0–6.0)
Remogliflozin etabonate (prodrug) PK Parameter RE BID MET + RE BID
N = 12-13a N = 12-13a
AUC(0–last) (h.ng/mL) 98.9 (69) 102.1 (49)
Cmax (ng/mL) 79.5 (107) 67.7 (77)
tmax (h) 3.0 (1.0–4.0) 3.0 (1.0–6.0)
Remogliflozin (active entity) PK Parameter RE BID MET + RE BID
N = 13 N = 13
AUC(0–12) (h.ng/mL) 6814.3 (33) 6425.9 (33)
Cmax (ng/mL) 2688.6 (52) 2124.6 (63)
tmax (h) 3.0 (1.0–4.0) 3.0 (1.0 - 6.0)
GSK279782 (active metabolite) PK Parameter RE BID MET + RE BID
N = 13 N = 13
AUC(0–12) (h.ng/mL) 1527.9 (37) 1472.9 (36)
Cmax (ng/mL) 462.8 (39) 361.9 (38)
tmax (h) 4.0 (1.0–4.0) 4.0 (1.0–8.0)
Values are geometric mean (%CVb) for each parameter, except for tmax which is median (range). PK, pharmacokinetic; MET BID, metformin 500 mg every 12 hours;
MET + RE BID, metformin 500 mg + remogliflozin etabonate 500 mg every 12 hours; RE BID, remogliflozin etabonate 500 mg every 12 hours.
a AUC not evaluable for one subject.
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profiles are provided in Figures 2, 3, 4. There were no ef-
fects of metformin on the AUC of remogliflozin etabonate,
remogliflozin, or its metabolite, GSK279782. However, Cmax
was lower with the combination. For Cmax, on average,
there was a decrease of 21% in remogliflozin and a decrease
of 22% in GSK279782 with MET+RE compared to
remogliflozin etabonate alone. The 90% CI indicates that
the true difference lies between a decrease of 40% and an
increase of 5% for remogliflozin and between a decrease of
33% and 9% for GSK279782.Table 3 Statistical comparisons of PK parameters of metform
GSK279782 with and without remogliflozin etabonate
Compound PK parameter Treatmen
Metformin AUC(0–12) [1] MET +
Cmax MET +
Remogliflozin etabonate (prodrug) AUC(0-last) MET
Cmax MET
Remogliflozin (active entity) AUC(0–12) MET
Cmax MET
GSK279782 (active metabolite) AUC(0–12) MET
Cmax MET
[1] primary comparison; MET + RE, metformin 500 mg + remogliflozin etabonate 500Pharmacodynamics
Fasting plasma glucose
A summary of the FPG concentration data by treatment
period and study day is presented in Figure 5. When the
changes in fasting plasma glucose concentrations from
baseline (pre-dose on Day 1) to Day 2 and Day 3 were con-
sidered for the three treatment periods, it appeared that the
fasting glucose concentrations remained relatively stable
during the MET BID period, whereas small decreases were
observed during both the RE BID and MET+RE BID treat-
ment periods.in, remogliflozin etabonate, remogliflozin, and
t comparison Point estimate (GLSM Ratio) 90% CI
RE / MET 1.05 (0.98, 1.12)
RE / MET 1.01 (0.92, 1.10)
+ RE / RE 1.00 (0.77, 1.29)
+ RE / RE 0.85 (0.54, 1.35)
+ RE / RE 0.94 (0.86, 1.04)
+ RE / RE 0.79 (0.60, 1.05)
+ RE / RE 0.96 (0.92, 1.01)
+ RE / RE 0.78 (0.67, 0.91)
mg every 12 hours; GLSM : Geometric least-squares mean.
Figure 1 Mean metformin concentration (and standard
deviation) vs. time profiles with and without remogliflozin
etabonate, n = 13.
Figure 3 Mean remogliflozin (active entity) concentration (and
standard deviation) vs. time profiles with and without
metformin, n = 13.
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excreted
Mean cumulative 24-hour urinary glucose excretion was
approximately 500 mmol following treatment with RE
BID or MET + RE BID (Day 2), whereas MET BID had
relatively no effect on urine glucose output (Table 4).Figure 2 Median remogliflozin etabonate (prodrug)
concentration vs. time profiles with and without metformin,
n = 13. (Median data is presented in this plot because the majority
of the samples were below the lower limit of quantification).The effect of remogliflozin etabonate on urine glucose
excretion was not diminished by co-administration with
metformin. The greatest increase in urine glucose ex-
cretion was evident within the first 4 hours of dosing
following both remogliflozin etabonate regimens. The
24-hour creatinine clearance on Day 2 was comparable
across the three treatment periods and was approxi-
mately 110 mL/min. During the RE BID and MET + RE
BID periods, mean and median values for the percentFigure 4 Mean GSK279782 (active metabolite) concentration
(and standard deviation) vs. time profiles with and without






































Figure 5 Fasting plasma glucose concentration (FPG; mmol/L) – Change from baseline (pre- dose on Day 1 of each treatment period).
MET BID, metformin 500 mg every 12 hours; RE BID, remogliflozin etabonate 500 mg every 12 hours; MET + RE BID, metformin 500 mg +
remogliflozin etabonate 500 mg every 12 hours. Mean (and standard deviation) baseline FPG values for each treatment period: MET BID: 6.72
(1.88); RE BID, 6.98 (2.06); MET + RE BID, 6.42 (1.15).
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43% up to 68% during the individual collection inter-
vals, with a mean of approximately 50% for the combined
24 hour collection for both remogliflozin etabonate
containing regimens compared to 1.4% with metformin
alone (Table 5).
Fluid balance
Total fluid intake, total urine volume, and fluid balance
data for the 24-hour collection intervals on Days 1 and 2
and the initial 12-hour collection interval on Day 3 were
compared by treatment. On Days 1 and 2, mean total
24-hour fluid intake ranged from approximately 2500 mL
to 3000 mL across the three treatment periods. During the
12-hour collection period on Day 3, mean fluid intake
ranged from approximately 1800 to 2200 mL for any one
treatment period. Because fluid intake was less than total
urine volume throughout all treatment periods, mean fluid
balance values were considered negative during most inter-
vals. On Day 1, fluid balance (median, range) appeared
more negative on RE BID (-1145 mL, -1630 to +335 mL)Table 4 Summary of 24-hour urine glucose (mmol) on
day 2 by treatment
Met BID RE BID Met + RE BID
N = 13 N = 13 N = 13
Mean (SD) 13.6 (13.4) 528 (130) 458 (98)
Median 10.9 497 485
Min, Max 1.1, 43.9 384, 796 242, 573and MET+ RE BID (−1200 mL, -2395 to −90 mL) com-
pared to MET BID (−775 mL, -2280 to +400 mL). Fluid
balance neutrality seemed to be reached on Day 3 for all
drug regimens.
Safety and tolerability
There were no serious adverse events reported. The
only adverse event considered related to study drug
was hypoglycemic symptoms reported by 2 subjects,
one event with metformin alone and one with MET +
RE. However, plasma glucose measurements were un-
fortunately not performed to confirm hypoglycemia.
In both cases, the symptoms of hypoglycemia were
considered mild in intensity. The events were reported
in the time before scheduled meals; the symptoms re-
solved with provision of food, and did not require a
change in study drug. Back pain and headache were the
only events reported by more than one subject during
any treatment period (reported during MET BID by 2
different subjects). All adverse events are summarized
in Table 6.Table 5 Summary of percent filtered glucose excreted in
urine on day 2 by treatment
Met BID RE BID Met + RE BID
N = 13 N = 13 N = 13
Mean (SD) 1.41 (1.52) 51.3 (7.02) 48.7 (9.87)
Median 0.95 51.8 49.3
Min, Max 0.10, 4.71 38.4, 61.3 35.7, 67.9
Table 6 Summary of adverse events by treatment
Preferred term MET BID RE BID MET + RE BID
N = 13 N = 13 N = 13
n (%) n (%) n (%)
Any Event 5 (38%) 2 (15%) 7 (54%)
Headache 2 (15%) 0 1 (8%)
Back pain 2 (15%) 0 0
Muscle spasms 1 (8%) 1 (8%) 0
Hypoglycemia 1 (8%) 0 1 (8%)
Neck pain 1 (8%) 0 0
Osteoarthritis 0 0 1 (8%)
Abdominal pain upper 0 1 (8%) 0
Dyspepsia 0 0 1 (8%)
Toothache 1 (8%) 0 0
Dizziness 1 (8%) 0 0
Fatigue 1 (8%) 0 0
Nasopharyngitis 0 0 1 (8%)
Wound 0 0 1 (8%)
Rash 0 0 1 (8%)
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eters or vital signs were reported for any treatment
regimen. As an increased exposure to metformin can
result in lactic acidosis, lactic acid levels were mea-
sured. While there were no instances of lactic acidosis,
a trend toward increasing lactic acid was observed with
metformin monotherapy relative to regimens including




















Figure 6 Lactic acid concentration by treatment (normal range of 0.5
remogliflozin etabonate 500 mg every 12 hours; MET + RE BID, metformin 5Discussion
Despite the availability of multiple classes and combina-
tions of antihyperglycemic agents, the clinical management
of T2DM is currently suboptimal, with the majority of pa-
tients failing to achieve and maintain target glycemic levels
in practice [38]. Consequently, there is a continued need
for novel therapeutic approaches, particularly those with
complementary modes of action that will enable further
improvement of glycemic control.
Remogliflozin etabonate, by inhibiting glucose re-
absorption, offers a potential treatment for T2DM as
monotherapy and in combination with existing therap-
ies. Remogliflozin etabonate is being developed for use
for the treatment of T2DM as monotherapy, and in
combination with existing therapies including metfor-
min. In this study, no effect of remogliflozin etabonate
on metformin PK parameters was observed. The findings
from this study are consistent with the reported lack of
inhibition by remogliflozin etabonate, remogliflozin, and
GSK279782 on a panel of metabolic enzymes and trans-
porters, including organic cation transporters involved
with metformin renal secretion [39].
This study was not adequately powered to test the ef-
fect of metformin on remogliflozin etabonate PK param-
eters. Metformin did not appear to affect the AUC of
remogliflozin etabonate, remogliflozin and its metabolite;
however, Cmax was lower after the co-administration
of remogliflozin etabonate and metformin than with
remogliflozin etabonate alone. Under the conditions of this
study, the peak plasma concentration of remogliflozin con-
siderably exceeded the concentration required for full500 mg BID
+
+






to 2.2 mmol/L). MET BID, metformin 500 mg every 12 hours; RE BID,
00 mg + remogliflozin etabonate 500 mg every 12 hours.
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that a clinically significant decrease would be observed
when administering the combination if low doses of
remogliflozin etabonate or considerably higher doses of
metformin were given.
As expected on the basis of its pharmacological prop-
erties, the administration of remogliflozin etabonate
with or without metformin greatly increased urine
glucose excretion and the percent of filtered glucose
excreted in the urine. The evidence of pharmacological
effect was seen within the first 4 hours of dosing with
remogliflozin etabonate and sustained while on treat-
ment. Co-administration of metformin with remogliflozin
etabonate did not diminish the glucosuric effect of
remogliflozin etabonate. Only small changes in fasting glu-
cose concentration were observed during both the RE BID
and MET + RE BID treatment periods for this cohort of
subjects with good glucose control. Mean fasting glu-
cose concentrations were <7 mmol/L on Day −1 of each
treatment period, leaving little room for substantial
improvement.
Concomitant administration of remogliflozin etabonate
with metformin for 3 days was well tolerated in subjects
with T2DM. Hypoglycemia was the only adverse event
that was considered related to study drug (and occurred
with metformin alone, as well as with the combination).
However, neither case was confirmed with plasma glucose
concentrations. Antidiabetic treatments that increase
urine glucose may increase risk of urinary tract infections
(UTIs); however, no documented UTIs were observed
over the limited duration of remogliflozin etabonate treat-
ment in this study. Mean lactate concentrations showed
an increase or increasing trend during the three day
MET BID treatment period. In contrast, mean lactate
concentrations are unchanged or decreased slightly
during RE BID and MET + RE BID periods. Potential
mechanisms to explain the decreased lactate concentra-
tions include reduced glucose concentrations with less
production from glycolysis, enhanced extraction of lac-
tic acid by the liver for gluconeogenesis or increased
clearance of lactic acid by the kidney. No symptoms
suggestive of lactic acidosis occurred during the study.
Conclusions
In summary, the findings of this study do not indicate a
safety concern when multiple oral doses of remogliflozin
etabonate 500 mg are administered with metformin 500
mg BID in the intended patient population. Because
remogliflozin etabonate does not affect the PK profile of
metformin, there is a low risk for adverse events resulting
from a PK drug interaction and increased metformin
exposure. The approximate 20% decline in remogliflozin
Cmax under conditions of coadministration is likely a re-
flection of the 15% decline in the Cmax of the prodrug(RE) when given with metformin (Table 3). It appears that
metformin reduces the Cmax of RE without an effect on
RE AUC, suggesting a change in the shape of the 12-hour,
steady state, concentration-time profile. Even though the
confidence interval is wide for the prodrug Cmax point esti-
mate (0.54, 1.35) and contains 1.0, it is plausible that
coadministration of metformin altered GImotility enough to
affect the absorption or hydrolysis of RE resulting in a lower
Cmax of RE. The lower Cmax values for remogliflozin and
GKS279782 following dosing with metformin collectively
support this conclusion since they are downstream metabo-
lites of RE.
Although administration with metformin resulted in a
21% reduction in Cmax, the PD properties of remogliflozin
etabonate were not altered when administered with metfor-
min. There was an indication that remogliflozin etabonate
alone improves plasma blood glucose by increasing the
excretion of urine glucose, and this effect by remogliflozin
etabonate was not impaired by the co-administration of
metformin. Future studies in a larger patient population are
warranted to definitively test the safety and efficacy of
remogliflozin etabonate in combination with metformin in
patients with T2DM who have not achieved the desired
glycemic target.
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